Umeclidinium bromide/vilanterol
|
Umeclidinium bromide (TOP), vilanterol (BOTTOM) | |
| Combination of | |
|---|---|
| Umeclidinium bromide | Muscarinic antagonist |
| Vilanterol | Ultra-long-acting β2 agonist |
| Clinical data | |
| Trade names | Anoro Ellipta |
| AHFS/Drugs.com | entry |
| Pregnancy category |
|
| Routes of administration | Inhalation (DPI) |
| Legal status | |
| Legal status |
|
| Identifiers | |
| ATC code | R03AL03 (WHO) |
Umeclidinium bromide/vilanterol (trade name Anoro Ellipta) is a combination drug approved for the treatment of chronic obstructive pulmonary disease (COPD).[1][2] It is applied as an inhalation.
References
- ↑ Feldman, GJ; Edin, A (2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: Current evidence and future prospects". Therapeutic advances in respiratory disease 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659.
- ↑ "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 09, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.